Overview of the use of implantable venous access devices in the management of children with inherited bleeding disorders.
Frequent infusion of factor concentrates may be challenging in young boys with haemophilia, especially if their disease is complicated by inhibitors. A central venous access device (CVAD) is often placed in young patients in need of repeated infusions for prophylaxis or immune tolerance induction. Although user friendly and capable of providing reliable venous access, these devices are associated with a high complication rate over time. In the haemophilia population, major complications include CVAD-associated infections and deep venous thrombosis, which is most often silent. Established risk factors for catheter-related infection include age less than 6 years at the time of CVAD placement and use of an external CVAD when compared with a totally implantable device such as a port. Avoidance of CVAD-related infections is facilitated by strict adherence to aseptic technique. The risk of deep venous thrombosis appears related to the duration for which the catheter is in place, with the risk increasing beyond 4 years. The promotion of a strict clinic policy in which CVADs are left in place for as short a time as possible should decrease the risk of complications. In rare cases where a totally implantable CVAD cannot be placed for technical reasons, an arteriovenous fistula may provide reliable venous access. In all cases, however, venous access via peripheral veins is preferred over CVADs.
Komvilaisak
P
P
Division of Haematology/Oncology, The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada.
Connolly
B
B
Naqvi
A
A
Blanchette
V
V
D002405:Catheterization, Central Venous / Q000009:adverse effects / Q000379:methods*; D002408:Catheters, Indwelling / Q000009:adverse effects; D002648:Child; D002675:Child, Preschool; D003029:Coagulants / Q000008:administration & dosage*; D004866:Equipment Contamination / Q000517:prevention & control; D006467:Hemophilia A / Q000150:complications / Q000628:therapy*; D006801:Humans; D007223:Infant; D008297:Male; D020246:Venous Thrombosis / Q000517:prevention & control
D003029:Coagulants